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The iron chelators desferrioxamine and 1,2-dimethyl-3-hydroxypyrid-4-one (Ll) inhibited human platelet aggregation in 
vitro as well as thromboxane A, synthesis and conversion of arachidonate to lipoxygenase-derived products. Non-chelat- 
ing compounds related to Ll were without effect on cyclooxygenase or lipoxygenase activity. Since both cyclooxygenase 
and lipoxygenase are iron-containing enzymes, it is suggested that the inhibition of platelet function by these iron chela- 
tors may be related to the removal or binding of iron associated with these enzymes. These iron chelators may therefore 
be of potential therapeutic value as platelet antiaggregatory agents and of possible use in the treatment of atherosclerotic 
and inflammatory joint diseases. 
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1. INTRODUCTION 
Despite the fact that the main clinical use of the 
iron chelators desferrioxamine (DFO) and 
1 ,Zdimethyl-3-hydroxypyrid4-one (Ll) is the 
treatment of iron overload [ 11, these chelators may 
have other potential clinical uses where iron- 
containing enzymes [2] regulate metabolites which 
contribute to the pathogenesis of disease. For ex- 
ample, a recent study has demonstrated that DFO 
and Ll inhibit prostanoid synthesis by vascular 
tissue through binding of iron associated with 
cyclooxygenase. Since certain prostanoids are pro- 
inflammatory, it was suggested that iron chelators 
may prove beneficial in the treatment of inflam- 
matory and other diseases through inhibition of 
cyclooxygenase [3]. It has also been proposed that 
platelets and their released products may play a 
role in the pathophysiology of inflammatory and 
atherosclerotic disease [4-71. 
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With regard to atherosclerosis, it has been sug- 
gested that platelets may adhere to existing 
atherosclerotic plaques, releasing substances 
(thromboxane AZ (TXAz), lipid peroxides, growth 
factors) whose chemotactic, vasoconstrictor and 
mitogenic properties may further accelerate the 
atherogenic process [5-lo]. Cyclooxygenase and 
lipoxygenase also possess the potential to generate 
other oxygen free radicals, which may also con- 
tribute to platelet-mediated vascular pathogenesis 
[11,12]. 
Although little is known of the role of platelets 
in inflammatory joint disease, it is well established 
that prostanoids and leukotrienes play a cardinal 
role in the aetiology of this disorder [3,7]. In this 
context, it has been demonstrated that rheumatoid 
synovial membranes contain large amounts of iron 
[ 131, and that intraplatelet iron is elevated in pa- 
tients with ankylosing spondylitis [14]. It is thus 
possible that there is an aetiological link between 
elevated intraplatelet iron, increased cycloox- 
ygenase and lipoxygenase activity and proinflam- 
matory hydroperoxyeicosanoid synthesis. 
We therefore investigated the effect of DFO and 
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Ll and of non-chelating structural analogues of L 1 
on human platelet aggregation and TXA;? syn- 
thesis. Platelet lipoxygenase activity in the 
presence of these chelators was also assessed since 
products of this iron-containing enzyme are also 
thought to play a role in the pathogenesis of in- 
flammation and atherosclerosis [7]. 
2. MATERIALS AND METHODS 
2.1. Iron chelators 
1,2-Dimethyl-3-hydroxypyrid-4-one (L 1) was prepared as 
previously described [ 151. 3-Hydroxy-2-methylpyr-4-one 
(maltol), 4-hydroxy-6-methylpyr-2-one and 2,4-dihydro- 
pyridine were obtained from Aldrich Chemical Company, 
Gillingham, Dorset, England. Desferrioxamine was a gift from 
Ciba Geigy England, Horsham, Sussex, England. 
2.2. Platelet aggregation and thromboxane AZ relerise 
Blood was collected (from an antecubital vein) with minimal 
stasis from 10 healthy volunteers who denied taking any drugs, 
particularly nonsteroidal antiinflammatory drugs, for the 
previous 2 weeks. The blood was anticoagulated with 3.8% 
(w/v) trisodium citrate (9 parts blood to 1 part citrate) as 
previously described [16]. Platelet rich plasma (PRP) and 
platelet poor plasma (PPP) were prepared by centrifugation at 
room temperature. Aggregations were carried out in Chronolog 
dual channel aggregometers (Coulter Electronics, Luton, Beds., 
England). Aggregation was expressed as the percentage fall in 
absorbance between PRP and PPP 3 min after adding ag- 
gregating agents (collagen, adenosine diphosphate (ADP) and 
adrenaline). The agonist concentration selected was that which 
generated just submaximal aggregation (ADP: median agonist 
concentration 6 pmol/l; range 2-10 pmol/l; adrenaline: 
3 pmol/l; range OS-5 fimol/l; collagen: 0.7 mg/l; range 
0.3-l .O mg/l). Iron chelators dissolved in autologous plasma 
were added to the PRP 5 min prior to the addition of agonists. 
As a further control, the effect of iron chelators on aspirin- 
treated platelets was also investigated. Measurement of TXAs 
release was carried out as previously described [16]. Briefly, 
3 min after adding agonists the PRP was added to absolute 
ethanol to stop the reaction. This sample was stored at - 70°C 
until measurement of thromboxane B2 (TXBs; the spontaneous, 
stable breakdown product of thromboxane AZ) in a single batch 
using a specific radioimmunoassay [16]. 
2.3. Platelet thromboxane AZ synthesising capacity 
PRP aliquots were centrifuged in an Eppendorf ultracen- 
trifuge and platelet pellets were washed with normal saline. The 
pellets were then frozen to -70°C and thawed, and Krebs 
Ringer bicarbonate buffer, including varying concentrations of 
the iron chelators, was added. The samples were then sonicated 
for 10 s in a Soniprep 150 sonicator (MSE, Crawley, Sussex, 
England). The pellets were then incubated at 37’C for 1 h after 
which time an aliquot of the supernatant was taken for estima- 
tion of TXBs by radioimmunoassay as previously described 
[17]. This procedure is an index of total synthesising capacity of 
TXAs by platelets [17]. 
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2.4. Platelet lipoxygenase activity 
Tris buffer (100 mmol.l-‘, pH 7.4), containing 1 mM EDTA 
(1 mmol.l-‘), varying concentrations of iron chelators and 
50 nCi [‘?]arachidonate (1 Ci.mmol-‘; New England 
Nuclear, Dreieich, FRG) was added to the pellets as described 
above. The pellets were then sonicated and incubated at 37°C 
for 30 min. Incubates were extracted with ethyl acetate, and the 
lipoxygenase and cyclooxygenase products and the unchanged 
arachidonate (AA) were separated by thin-layer 
chromatography 1181. Zones corresponding to hydroxy- and 
hydroperoxyeicosatetraenoic acids (HETE and HPETE) were 
removed and counted for radioactivity, and percentage conver- 
sion of labelled arachidonate into lipoxygenase products was 
calculated. 
3. RESULTS AND DISCUSSION 
Both DFO and Ll inhibited platelet aggregation 
(table 1) and concomitant TXA2 release (table 2) in 
dose-dependent manners. The relative sensitivity 
of the aggregatory agonists (adrenaline > 
collagen > ADP) to the iron chelators indicates 
that the inhibition of platelet aggregation is likely 
to be due to an inhibition of TXA2 synthesis 
[16,17,19]. For example, the same pattern of in- 
Table 1 
Effect of 1,2-dimethyl-3-hydroxypyrid-4-one (Ll) and 
desferrioxamine (DFO) on agonist-stimulated platelet 
aggregation 
Control 1 2 4 8 
Ll (mm01 .I-‘) 
ADP 
(40:70) (4?75) (3;!65) (z2) (O?O) 
Adren- 
aline 
(42:90) (7&O) (2;2;7) (2?2) (i; 
Collagen 68 
(40-77) (5?90) (?S9) (O!l2) ,:; 
DFO (mmol .I-‘) 
ADP 
(406477) (2?54) (03i;4) (lP:9) 
Adren- 
aline 
(506& (3:1;(o) &) (:“;9) 
Collagen 65 
(40-93) (2&S) (tz2) (oz2) 
Platelet aggregation (070 fall in absorbance) is expressed as 
median and (range). PRP was prepared from 10 healthy control 
subjects. For agonist concentrations, see text. * P < 0.01; 
control vs drug. Wilcoxon rank sum test for paired samples 
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Table 2 Table 3 
Effect of 1,2-dimethyl-3-hydroxypyrid-4-one (Ll) and 
desferrioxamine (DFO) on agonist-stimulated TXAz release by 
human platelets 
Effect of 1,2-dimethyl-3-hydroxypyrid-4-one (Ll) and 
desferrioxamine (DFO) on agonist-stimulated and aspirin 
(ASA) inhibited platelet aggregation 
Control 1 2 4 8 
Ll (mmol.l-‘) 
ADP 
$16) (81414) (5112) (31;) (Z) 
Adren- 
aline 
(ZO23) (l:szO) (lZ2) cc;, (Z) 
Collagen 27 
(22-31) (2;:30) (1?:2) (K3) (41;) 
DFO (mmol .1-t) 
ADP 
(&3) (3:) (Z) (Z) (Z) 
Adren- 
aline 
(10!!20) (Z4) (24:) (Z) (Z) 
Collagen 
(172-42g) $5) (I?) 
0* 
(Cl) (Z) 
TXAz release (ng . ml-’ PRP) is expressed as median and 
(range). PRP was prepared from 10 healthy control subjects. 
For agonist concentrations, see text. * P < 0.01; control vs 
drug. Wilcoxon rank sum test for paired samples 
Control DFO ASA DFO + ASA 
(2 mmol/l) (0.55 mmol/l) (2 mmol/l + 
0.55 mmol/l) 
ADP 
(606369) (313-354) 
Adrenaline 75 
(60-80) (5-ss) 
Collagen 
(5g6470) (102_02) 
Control Ll ASA Ll +ASA 
(4 mmol/l) (0.55 mmol/l) (4 mmol/l + 
0.55 mM) 
ADP 
(65TgO) (4:56) 
Adrenaline 72 
(70-74) $1 I) 
Collagen 
(678-490) ( 1 Oy67) 
Platelet aggregation (S fall in absorbance) is expressed as 
median and (range). PRP was prepared from four healthy 
control subjects. For agonist concentrations, see text 
hibition of platelet aggregation has been observed 
with aspirin [ 191, indomethacin [20], tiaprofenic 
acid [20], ethanol [16] and the ‘classical’ TXAz 
synthase inhibitor, 1-IV-butyl imidazole [ 191. Fur- 
thermore, in the present study, inhibitory doses of 
DFO and Ll did not markedly alter the 
characteristic inhibitory action of aspirin on ADP-, 
adrenaline- or collagen-stimulated aggregation 
(table 3), consolidating the conclusion that these 
chelators are inhibiting aggregation through in- 
hibition of TXA2 synthesis. This interpretation 
was confirmed in the platelet pellets, since both 
DFO and Ll inhibited the maximal TXAZ-syn- 
thesising capacity of freeze-thawed-sonicated 
platelets (fig.1). This latter method of assessing 
platelet TXA;! synthesis obviates a priori aggrega- 
tion and is an index of the activity of TXA2 syn- 
thesising enzyme, viz. phospholipase AZ, 
cyclooxygenase and TXA2 synthase [ 171. 
-log [chelator7 ( mol I-’ ) 
Since there is no evidence that either PLA2 or 
TXAz synthase require trivalent cations and 
cyclooxygenase contains haem [21,22], it is sug- 
Fig.1. Effect of DFO (o), Ll (A), malt01 (v), 
4-hydroxy-6-methylpyr-2-one (0) and 2,4_dihydroxypyridine 
(v) on human platelet TXAz synthesis of human freeze-thawed- 
sonicated platelets. Each point represents mean & SE, n = 10. 
I&s: Ll, 2 x lO-3 mol.l-‘; DFO, 7 x lO-4 mol.l-‘; maltol, 
8 x lo-” mol.l-‘. 
(344553) (313244) 
(3_7!3) (2?10) 
(09 (09 
60 
(57-62) (404-855) 
(12%) (r&l) 
(0%) (OJ)22) 
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I 
0-5 
I 1 
3 2 
-log [chelated ( mol.l-‘) 
Fig.2. Effect of DFO (o), Ll (A), malt01 (v), 
4-hydroxy-6-methylpyr-2-one (0) and 2,4-dihydroxypyridine 
(v) on conversion of arachidonate to HETE and HPETE by 
human platelets. Each point represents mean + SE, n = 10. 
K&s: Ll, 1.6 x lo-‘mol.I-‘; DFO, 1.2 x 10-3mol~1-‘; 
maltol, 8 x 10e3 mol.l-‘. 
gested that the iron chelators are inhibiting platelet 
aggregation through removal (or binding) of iron 
associated with cyclooxygenase in a manner similar 
to that previously observed with vascular pro- 
stacyclin synthesis [3]. That DFO and Ll are acting 
non-specifically on cyclooxygenase and lipox- 
ygenase is discounted since non-chelating com- 
pounds related to Ll were without effect (figs 1 
and 2) and maltol, a weaker chelator than DFO or 
Ll was of intermediate potency (figs 1 and 2). Fur- 
thermore, the presence of trivalent cations, iron 
and aluminium, reversed the inhibitory action of 
DFO and Ll on platelet TXAZ synthesis (table 4), 
presumably through negation of the iron binding 
capacity of the chelators. Although not proving 
the involvement of iron, these data consolidate the 
above point that Ll and DFO are not acting non- 
specifically on cyclooxygenase. 
The present study also demonstrates that DFO 
and Ll inhibit platelet lipoxygenase activity (fig.2), 
an action which is also reversed by the addition of 
exogenous iron and aluminium (table 4). Since it 
has been established that human platelet lipox- 
ygenase contains non-haem iron [23], it is likely 
that these chelators are inhibiting lipoxygenase ac- 
tivity through the removal or binding of iron 
associated with this enzyme. 
In contrast to the present findings, it has been 
reported by Morgan et al. [24] that DFO enhances 
the conversion of exogenous AA to PGI2 but 
diminishes lipoxygenase activity in homogenates of 
the rat uterus [24]. In a previous study, however, 
we found that AA-stimulated PGI2 by intact rat 
aortic tissue was inhibited by DFO and Ll [3]. 
Thus, the only apparent difference in methodology 
which might explain this disparity is that Morgan 
et al. investigated homogenised tissue. 
In addition to the inhibition of free radical 
damage induced by non-protein-bound iron [25], 
the inhibition of platelet activity by these chelators 
may also be useful in the treatment of thrombotic, 
atherosclerotic and inflammatory diseases via 
several mechanisms: firstly, as antithrombotic 
agents through inhibition of platelet aggregation 
and TXA2 release; secondly, in atherogenesis as in- 
hibitors of platelet adhesion, growth factor release 
and lipid peroxidation; thirdly, as inhibitors of 
proinflammatory hydroperoxyeicosanoid syn- 
Table 4 
Effect of Fe’+ and A13+ on DFO- and Ll-inhibited platelet TXA2 and lipoxygenase activity 
(percentage inhibition f SD, n = 10) 
3mMLl 3mMLl+ 3mMLl+ 3mMLl+ 3mMLl+ 
1 mM Fe3+ 3 mM Fe3+ 1 mM AIS+ 3 mM A13+ 
TXA2 inhibition 75 f 10 50 f 12 10 + 4 48 f 6 8+1 
Liooxvaenase inhibition 8Ok 6 45+ 8 12 * 2 53 f 8 8+2 
2mMDF0 2mMDFO+2mMDFO+2mMDFO+2mMDFO+ 
1 mM Fe” 2 mM Fe’+ 1 mM Al’+ 2 mM A13+ 
TXA2 inhibition 85 + 10 40f 4 2 * 0.2 39 * 3 2 + 0.1 
Lipoxygenase inhibition 81 k 12 38zt 3 4 f 0.1 42 + 4 8 + 0.4 
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thesis; and finally, through inhibition of toxic free 
radical generation. These mechanisms may apply 
not only to platelets but also to leukocytes, since 
these cells also release hydroperoxyeicosanoids [6]. 
It should be noted, however, that DFO, Ll and 
possibly other chelators can only be used in the 
above conditions if sufficient therapeutic non- 
toxic concentration ranges are reached in vivo. The 
indications are that in some cases this may have oc- 
curred with DFO, where doses of up to 235 mg/kg 
were used in thalassaemia patients [26], since it is 
known that plasma concentrations exceeding 
300 pmol/l could be achieved with a dose of DFO 
of 80 mg/kg in haemodialysis patients [27]. The 
design and screening of more chelators of the CY- 
ketohydroxypyridine [28-301 or the desferriox- 
amine [31] classes, which could be more specific 
than Ll and DFO in inhibiting lipoxygenase and 
cyclooxygenase at lower doses and their interaction 
with other inhibitors of these enzymes, is currently 
under investigation. 
REFERENCES 
111 
121 
[31 
[41 
VI 
161 
171 
(81 
191 
[23] Aharony, D., Smith, J.B. and Silver, M.S. (1980) Fed. 
Proc. 39, 424-428. 
Kontoghiorghes, G.J., Aldouri, M.A., Hoffbrand, A.V. 
et al. (1987) Br. Med. J. 295, 1509-1512. 
Kontoghiorghes, G.J. (1987) in: Free Radicals, Oxidant 
Stress and Drug Action (Rice-Evans, C. ed.) pp.277-303, 
Richelieu Press, London. 
Jeremy, J.Y., Kontoghiorghes, G.J., Hoffbrand, A.V. 
and Dandona, P. (1988) Biochem. J. 254, 239-244. 
Lewis, G.P. (1983) Br. Med. Bull. 39, 243-248. 
Chesterman, C.N. and Berndt, M.C. in: Clinics in 
Haematology (Chesterman, C.N. ed.) pp.l63-175, W.B. 
Saunders Co., London, Philadelphia, Toronto. 
Ross, R. (1986) New Engl. J. Med. 314, 485-500. 
Williams, T.J. (1983) Br. Med. J. 39, 239-242. 
Turner, S.L., Tainer, J.A. and Lynn, W.S. (1975) Nature 
257, 680-681. 
[24] Morgan, A., McDonald-Gibson, R.G. and Slater, T.F. 
(1986) IRCS Med. Sci. 14, 399-400. 
(251 Kontoghiorghes, G.J., Jackson, M.D. and Lunec, J. 
(1986) Free Radic. Res. Commun. 2, 115-126. 
[26] Davies, S.C., Hungerford, J.L., Arden, J.B., Marcus, 
R.E., Miller, M.H. and Huehns, E.R. (1983) Lancet ii, 
181-184. 
[27] Allain, P., Chalei, D., Mauras, Y. et al. (1987) Clin. 
Chim. Acta 170, 331-338. 
[28] Kontoghiorghes, G.J. (1982) The Design of Orally Active 
Iron Chelators for the Treatment of Thalassaemia, PhD 
Thesis, University of Essex, British Library Microfilm 
D66194/86. 
[29] Kontoghiorghes, G.J. (1986) Mol. Pharmacol. 30, 
670-673. 
Glavind, J., Hartmann, S., Clemmeson, J., Jessen, K.E. [30] Kontoghiorghes, G.J. (1988) Drugs Future 13, 413-416. 
and Dam, H. (1952) Acta Pathol. Microbial. Stand. 30, [31] Kontoghiorghes, G.J., Marcus, R.E. and Huehns, E.R. 
l-6. (1983) Lancet ii, 454. 
[IO] Harland, W.A., Gilbert, J.D. and Brooks, C.J.W. (1973) 
Biochim. Biophys. Acta 316, 378-385. 
[ 1 I] Mason, R.F., Kalyanamara, B., Tainer, B.E. and Elings, 
T.E. (1980) J. Biol. Chem. 255, 5019-5022. 
1121 Deby, C. (1988) in: Prostaglandins: Biology and 
Chemistry of Prostaglandins and Related Prostanoids 
(Curtis-Prior, P.B. ed.) pp.1 l-36, Churchill Livingstone, 
Edinburgh, London, Melbourne and New York. 
[13] Muirden, K.D. (1966) Ann. Rheum. Dis. 25, 387-401. 
[14] Hallgren, R., Fetelius, N. and Findh, U. (1987) J. 
Rheumatol. 14, 548-553. 
[15] Kontoghiorghes, G.J. and Sheppard, L. (1987) lnorg. 
Chim. Acta 136, Lll-L12. 
[16] Mikhailidis, D.P., Jeremy, J.Y., Barradas, M.A., Green, 
N. and Dandona, P. (1983) Br. Med. J. 287, 1495-1502. 
[17] Jeremy, J.Y., Mikhailidis, D.P., Thompson, C.S., 
Barradas, M.A. and Dandona, P. (1988) Diabet. Res., in 
press. 
[18] Hurst, J.S., Flatman, S. and McDonald-Gibson, R.G. 
(1987) in: Prostaglandins and Related Substances: A 
Practical Approach (McDonald-Gibson, R.G. et al. eds) 
pp.53-73, IRL Press, Oxford, Washington, DC. 
[19] Best, L.C., Holland, T.K., Jones, P.B.B. and Russell, 
R.G.G. (1980) Thromb. Haemost. 43, 38-40. 
[20] Jeremy, J.Y., Barradas, M.A., Mikhailidis, D.P. and 
Dandona, P. (1985) Pharmatherapeutica 4, 260-265. 
[21] Rittenhouse-Simmons, S. and Deykin, D. (1978) Biochim. 
Biophys. Acta 543, 409-422. 
[22] Kulmacs, R.J. and Lands, W.E.M. (1984) J. Biol. Chem. 
259, 6358-6363. 
109 
